title: Pitolisant: First Global Approval.
abstract: Pitolisant (Wakix™) is an inverse agonist of the histamine H3 receptor that is being developed by Bioproject. Oral pitolisant is approved in the EU for the treatment of narcolepsy with or without cataplexy in adults. Pitolisant has received a Temporary Authorization of Use in France for this indication in case of treatment failure, intolerance or contraindication to currently available treatment. Pitolisant has orphan drug designation in the EU and the USA. In the pivotal HARMONY I trial, pitolisant significantly decreased excessive daytime sleepiness versus placebo in adults with narcolepsy with or without cataplexy (primary endpoint). Pitolisant also significantly decreased cataplexy rate versus placebo in these patients. This article summarizes the milestones in the development of pitolisant leading to this first approval for narcolepsy.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
authors.forename: Yahiya Y
authors.initials: YY
authors.lastname: Syed
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D059331:Adrenergic Neurons / Q000187:drug effects; D000328:Adult; D000818:Animals; D002648:Child; D002986:Clinical Trials as Topic; D017442:Histamine Agonists / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D009290:Narcolepsy / Q000188:drug therapy*; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018100:Receptors, Histamine H3 / Q000502:physiology
chemical_list: D017442:Histamine Agonists; D010880:Piperidines; D018100:Receptors, Histamine H3; C516975:pitolisant